| Document |
Document Title |
|
WO/2000/048990A1 |
The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalami...
|
|
WO/2000/027627A1 |
In its first aspect, the invention is directed to a solid support mediated method for the synthesis of diverse polycyclic heterocycles according to general formula (V). A second aspect of the invention is directed to a solid support boun...
|
|
WO/1999/043662A1 |
The subject invention involves processes for making 2-oxopiperazine and homologous compounds using a solid support resin by (a) removing the protecting group from an N-protected amino acid ester of the resin (if present), (b) reacting th...
|
|
WO/1999/040047A1 |
The invention relates to methods for preparing macrocyclic products with 9 or more ring atoms by ring-closing diine metathesis of suitable diine substrates. The diine substrates can be converted into cycloakynes or into cycloalkadiines b...
|
|
WO/1999/020599A1 |
The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the inv...
|
|
WO/1998/051665A2 |
This invention relates to macrocyclic molecules of formula (I) which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). The present invention also relates to pharmaceutical compositions ...
|
|
WO/1998/030551A1 |
Macrocyclic compounds of formula (I) are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting comp...
|
|
WO/1998/023565A2 |
Aminoguanidine and alkoxyguanidine compounds, including compounds of formula $i((I)) wherein X is O or NR?9� and R?1�-R?4�, R?6�-R?9�, R?11�, R?12�, R?a�, R?b�, R?c�, Y, Z, n and m are set forth in the specification, ...
|
|
WO/1997/043268A1 |
Compounds of formula (I) wherein R1 is H, (C1-C5)alkyl, ORa, SRa, N(Ra)(Rb), halo, NO2, NHC(O)[(C1-C4)alkyl] or NHOH; R2 is a (C5-C22) hydrocarbyl group, optionally comprising 1-3 double bonds, 1-2 triple bonds or a mixture thereof, or (...
|
|
WO/1997/032860A1 |
Compounds of formula (I), wherein one of U and V is -CHR2-, and the other of U and V is selected from -N(COR4)-, -CH(COR4)-,-N(SO2R4)- and -CH(SO2R4)-, in which R2 is H, -COOR5, -CONR6R7 or -COR7 and R4 is H, C1 to C6 hydrocarbyl (in whi...
|
|
WO/1997/030992A1 |
This invention relates to compounds that inhibit farnesyl-protein transferase and ras protein farnesylation, thereby making them useful as anti-cancer agents. The compounds are also useful in the treatment of diseases, other than cancer,...
|
|
WO/1997/025324A1 |
The present invention concerns aza- and diazacycloheptane and cyclooctane compounds from the following formula (I) Ar1-A-B-Ar2 wherein Ar1, A, B, and Ar2 have the meanings given in the description. The compounds according to the inventio...
|
|
WO/1997/018207A2 |
This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tis...
|
|
WO/1996/040614A1 |
Compounds having anti-inflammatory and other activities are disclosed. The compounds are derived from diterpene and benzolactan phorboids.
|
|
WO/1996/031474A1 |
A compound of formula (I), in which Z is selected from (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and (k). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substitu...
|
|
WO/1996/030348A1 |
The present invention provides an efficient process of reacting a bis-indolyl acid of Formula (II), wherein R1 is a hydrogen or C1-C4 alkyl and R, X, and Y are optional substitutions; to produce a bis-indolyloxallic acid of Formula (III)...
|
|
WO/1996/004288A1 |
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotropic lateral sclerosis, Huntingto...
|
|
WO/1995/009160A1 |
A benzolactam derivative represented by general formula (I) and an antiretroviral drug containing the same as the active ingredient, wherein n represents an integer of 1 to 3; R1 represents linear or branched alkyl, or aralkyl; R2 repres...
|
|
WO/1995/007093A1 |
A topographic model useful to design and synthesize memory-enhancing substances is disclosed. Administration of substances designed by this method to enhance memory in mammals, including humans, is disclosed. Such substances include pept...
|
|
WO/1995/007269A1 |
The invention relates to retroviral protease inhibitors of the general formula (I): W-(A)n-B-(A*)m-V where W, A, B, A*, V, n and m are as defined herein, including related prodrugs of general formula (I) comprising a solubilising group w...
|
|
WO/1995/001967A1 |
The present invention relates to novel heterocyclic compounds having general formula (1) wherein: X is O, S, Se, or NR2; and A is (a) or (b) wherein W is O, S, NH or N-lower alkyl; with the proviso that when X is N-H or N-(aryl-methyl), ...
|
|
WO/1994/022840A1 |
This invention relates to novel substituted caprolactams, including 4-azacaprolactams such as those of formula (Ic) in which R4, R7, R22, and R27 are as defined in the description, and derivatives thereof which inhibit HIV protease and a...
|
|
WO/1994/022440A1 |
This invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibit...
|
|
WO/1994/019329A1 |
This invention relates to substituted cyclic carbonyls and derivatives thereof useful as Human Immnunodeficiency Virus (HIV) protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these com...
|
|
WO/1994/008977A1 |
This invention relates to novel substituted caprolactams of formula (I), including 4-azacaprolactams, and derivatives thereof which inhibit HIV protease and are useful for treatment of HIV disease. Also included in this invention are pha...
|
|
WO/1994/005671A1 |
The invention concerns an addition compound obtained by reacting C60 or C70 fullerenes with a diamine of formula (I) in which R1 is C2 to C4 alkylene or 1,2- or 1,3-cyclo-(C3 to C7)-alkylene and R2 and R3, which may be the same or differ...
|
|
WO/1993/009133A1 |
This invention relates to a method of inhibiting platelet aggregation, and 1,4-diazocine compounds which are mimics of the peptide sequence Arg-Gly-Asp.
|
|
WO/1993/007128A1 |
This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral...
|
|
WO/1993/007429A1 |
An air treatment plant, e.g. a freezing plant, for foodstuffs, comprises a housing (1), an elongate trough (11) provided therein for receiving the foodstuff to be treated, a heat exchanger (12) and a fan assembly (13) for producing an ai...
|
|
WO/1992/019665A1 |
This invention concerns cyclic aromatic amide oligomer compositions and a process for preparing such cyclic oligomers.
|
|
WO/1992/017460A1 |
Hydroxamic acid derivatives for use as medicaments, of formula (1), or a salt, solvate or hydrate thereof, in which R1 is hydrogen, C1-6alkyl, or -(CH2)n-A-R4 where n is from 0 to 6, A is a bond or an oxygen or sulphur heteroatom and R4 ...
|
|
WO/1992/012133A2 |
Compounds of formula (I), wherein Q, X, R?1�, R?2�, R?9� and Z are as defined in the text, including compositions containing said compounds and a method for using them to control arthropods.
|
|
WO/1992/006966A1 |
Thiol carboxylic acid derivatives, processes for their preparation and their use as collagenase inhibitors are described.
|
|
WO/1991/005549A1 |
Novel benzoheterocyclic compounds of formula (I), wherein R?1¿ is H, halogen, alkyl, optionally substituted amino, alkoxy; R?2¿ is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally ...
|
|
WO/1982/002199A1 |
New dibenzoxazonine, dibenz-oxazecine or dibenzo-oxaazacycloundecane derivatives and corresponding thia- and aza derivatives thereof, of the general formula I: (FORMULA) or a pharmaceutically acceptable acid addition salt or nitrogen oxi...
|
|
WO/1980/002155A1 |
An antibacterial surfactant containing in an effective amount at least one of cyclic amides represented by the following general formula; (FORMULA) (wherein R represents an alkyl group, alkenyl group, alkylaryl group, alkylarylalkyl grou...
|
|
JP7456757B2 |
An organic electroluminescence device according to an embodiment of the present disclosure includes a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode, in which the emissio...
|
|
JP7320821B2 |
To provide a polymer compound into which a functional molecule can be easily introduced.The polymer compound has at least one kind selected from the group consisting of a functional group represented by the following general formula (1) ...
|
|
JP2022171296A |
To provide a compound that has an azobenzene structure useful as a vesicle component.Provided is a compound that has an azobenzene structure represented by formula (1) (In the formula, one of R1 and one of R2 are -Z, -O-Z, -CO-O-Z, -O-CO...
|
|
JP7041687B2 |
Methods for making an arylomycin ring of formula tor salts or solvates thereof, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R5, R10 and Pg1 are as defined herein.
|
|
JPWO2020091054A1 |
Provision of a novel method for producing an isoquinoline-6-sulfonamide derivative useful as a medicine and an intermediate used therein. General formula (A)(In the formula, R4Indicates an amino-protecting group), a 1,4-diazocan compound...
|
|
JP2019510053A |
The present invention relates to compounds useful as inhibitors of cyclophilin and for the treatment of cyclophilin-related disorders and pharmaceutically acceptable compositions thereof.
|
|
JP6386026B2 |
The present invention relates to a compound, comprising a pyrene skeleton and arylamino groups, according to formula (I). The compound is suitable for use as a functional material in electronic devices.
|
|
JP2018039773A |
To provide a nitrogen-containing nine-membered cycloalkyne to which various functional parts can easily be introduced.Introduction of functional part(s) is made easy by making nitrogen(s) constituting a ring of a nitrogen-containing nine...
|
|
JP5989674B2 |
A thionating agent which is crystalline P 2 S 5 ·2 C 5 H 5 N.
|
|
JP2016076519A |
To provide a material for an organic electroluminescent element having high light-emitting efficiency and an organic electroluminescent element using the same.A compound formed by coupling tertiary amine through orthoterphenyl is contain...
|
|
JP5851929B2 |
A heterocyclic compound represented by Formula 1, and an organic layer including the heterocyclic compound: wherein Formula 1 is as defined in the specification. The organic light-emitting device including the heterocyclic compound has h...
|
|
JP5848698B2 |
The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, centr...
|
|
JP2015532268A |
The present invention relates to a method for producing a metathesis product comprising contacting a metathesis starting material with a metathesis catalyst under metathesis conditions, wherein the metathesis catalyst is reduced to half ...
|
|
JP5795619B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
